Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients with Recurrent Glioblastoma
A072201 is reopened to the Phase II portion of the study, effective September 19, 2025.
A072201 Safety Run-In is temporarily closed to accrual, effective January 3, 2025.
